Back to resultsClinical Trial of Quantitative Detection Kit for Hsp90α in Hepatic Cancer
Primary Purpose
Liver Cancer
Status
Unknown status
Phase
Not Applicable
Locations
China
Study Type
Interventional
Intervention
hsp90
Sponsored by
About this trial
This is an interventional diagnostic trial for Liver Cancer
Eligibility Criteria
Inclusion Criteria:
- Liver cancer patients
- Healthy volunteers,
- Benign liver diseases patients
Exclusion Criteria:
- Patients who Previously accepted radiotherapy
Sites / Locations
- Zhejiang Medical University Cancer Institute and Hospital
Arms of the Study
Arm 1
Arm Type
Experimental
Arm Label
liver cancer
Arm Description
Detect plasma Hsp90α concentration of liver cancer patients
Outcomes
Primary Outcome Measures
Hsp90α Concentration of plasma
Detect Hsp90α Concentration(ng/ml) of plasma and calculate the accuracy, specificity and sensitivity of Hsp90α kit
Secondary Outcome Measures
Full Information
1. Study Identification
Unique Protocol Identification Number
NCT02324127
Brief Title
Clinical Trial of Quantitative Detection Kit for Hsp90α in Hepatic Cancer
Official Title
Clinical Trial of Quantitative Detection Kit for Hsp90α in Hepatic Cancer
Study Type
Interventional
2. Study Status
Record Verification Date
December 2014
Overall Recruitment Status
Unknown status
Study Start Date
October 2012 (undefined)
Primary Completion Date
December 2014 (Anticipated)
Study Completion Date
December 2014 (Anticipated)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Protgen Ltd
4. Oversight
Data Monitoring Committee
No
5. Study Description
Brief Summary
Detect plasma Hsp90α concentration of liver cancer patients, healthy volunteers, benign liver diseases.
Detailed Description
Detect plasma Hsp90α concentration of liver cancer patients, healthy volunteers, benign liver diseases, validate accuracy, specificity and sensitivity of Hsp90α kit.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Liver Cancer
7. Study Design
Primary Purpose
Diagnostic
Study Phase
Not Applicable
Interventional Study Model
Single Group Assignment
Masking
None (Open Label)
Allocation
N/A
Enrollment
1100 (Anticipated)
8. Arms, Groups, and Interventions
Arm Title
liver cancer
Arm Type
Experimental
Arm Description
Detect plasma Hsp90α concentration of liver cancer patients
Intervention Type
Device
Intervention Name(s)
hsp90
Other Intervention Name(s)
biomarker
Intervention Description
Detect plasma Hsp90α concentration of lung cancer patients
Primary Outcome Measure Information:
Title
Hsp90α Concentration of plasma
Description
Detect Hsp90α Concentration(ng/ml) of plasma and calculate the accuracy, specificity and sensitivity of Hsp90α kit
Time Frame
4 months
10. Eligibility
Sex
All
Accepts Healthy Volunteers
Accepts Healthy Volunteers
Eligibility Criteria
Inclusion Criteria:
Liver cancer patients
Healthy volunteers,
Benign liver diseases patients
Exclusion Criteria:
Patients who Previously accepted radiotherapy
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Shusen Zhen, MD
Organizational Affiliation
The first hospital of Zhejiang province
Official's Role
Principal Investigator
Facility Information:
Facility Name
Zhejiang Medical University Cancer Institute and Hospital
City
Hangzhou
State/Province
Zhejiang
Country
China
12. IPD Sharing Statement
Learn more about this trial
Clinical Trial of Quantitative Detection Kit for Hsp90α in Hepatic Cancer
We'll reach out to this number within 24 hrs